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Phase I/II Study of a 3 Weekly Oral Taxane
(DJ-927) in Patients with Recurrent, Advanced Non-small
Cell Lung Cancer
Paul Baas, MD, PhD,* A. Szcze˛sna, MD,† I. Albert, MD,‡ J. Milanowski, MD,§ E. Juha´sz, MD,
Z. Sztancsik, MD,¶ J. von Pawel, MD,# R. Oyama, MS,** and S. Burgers, MD, PhD*
Introduction: A phase I/II study was performed to assess the
efficacy and toxicity of a new oral taxane in patients with recurrent,
advanced Non-small Cell Lung Cancer.
Patients and Methods: Patients who were treated with one prior,
taxane free chemotherapy regimen, were eligible for this study. A
single oral dose of DJ-927 (27 mg/m2) was given every 3 weeks. In
case of good tolerance, one dose escalation to 35 mg/m2 was
allowed. Response and toxicity were measured and plasma pharma-
cokinetic analysis was performed during the first course.
Results: From October 2004 to September 2005, 36 patients gave
informed consent and 34 received medication. The mean age was 58
years (range, 33–75 years). The majority of patients were pretreated
with a combination of cisplatin and gemcitabine. Median interval
between end of first treatment and the registration of this study was
7 months (range, 0.8–22 months). Twelve patients died on study of
which eight due to disease progression. In four patients with preex-
isting cardiac disease, toxicity led to cardiac worsening and subse-
quent death. Grade 3 and 4 toxicities according to the National
Cancer Institute Common Toxicity Criteria were neutropenia in 18
patients (53%), anemia in six patients (18%), nausea and fatigue in
two patients (6%), febrile neutropenia and neurotoxicity in one
patient (3%). The overall response rate for all patients was 5.6%
(Confidence Interval [CI] 0.7–18.7%). The percentage of patients
with stabilization for 6 weeks was 47%. The median time to
progression was 97 days (CI: 47–167 days) and the median survival
time was 120 days (CI: 68–222 days) for the ITT group. Since only
a minority of patients (3) tolerated the higher drug dose we omitted
this dose level because of hematological toxicity. Pharmacokinetic
analysis showed that the median area under the curve (t 0–168 hours)
was 1752  1355 ngr/ml/h and the half-life was 167  77 hours.
Conclusion: When administered once every 3 weeks, this oral
taxane formulation of DJ-927 was well-absorbed with a long termi-
nal half-life of 167 77 hour. DJ-927 has antitumor activity against
Non-small Cell Lung Cancer when given as second-line mono-
therapy (overall response rate in 5.6%; CI 0.7–18.7%). Ten patients
experienced SD for more than 8 weeks. Different types of dose
administration (metronomic dosing) or combination with other cy-
totoxic agents should be considered in future studies.
Key Words: Non-small cell lung cancer, Oral drug, Second line
treatment.
(J Thorac Oncol. 2008;3: 745–750)
Nearly all patients with advanced Non-small Cell LungCancer (NSCLC) experience tumor recurrences after
initial chemo (radiation) therapy. At the time of second line
treatment, many patients have a diminished performance
and are less fit for chemotherapy. Many studies have already
focused on oral formulations, as these seem less demanding
for patients than I.V. regimes. Medication can be taken
outside of the hospital and chronic treatment schedules can be
developed. For taxanes it has been shown that long lasting
plasma levels, which are considered to be in the active range,
can be obtained using oral formulations.1 One of the major
draw backs of oral taxanes is the limited bio-availability due
to the presence of a membrane-bound drug efflux pump in
intestinal cells (P-glycoprotein; P-gp) which pumps most of
the absorbed taxane back into the intestinal lumen. To over-
come this problem, P-gp inhibitors like cyclosporin-A are
coadministered to improve uptake and increase plasma levels.
However, timing, possible interactions and side effects of the
comedication make this approach less attractive.
In Europe, popular standard first line treatments of
NSCLC are platinum doublets with gemcitabine or vinorel-
bine, which makes second line treatment with a taxane
interesting from the point of view of noncross resistance.
Accepted standard second line therapy in NSCLC consists of
single agent docetaxel or pemetrexed. Each with comparable
activity but a different toxicity or cost profile.
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DJ-927 is a new semisynthetic molecular entity devel-
oped as an oral taxane anticancer agent. Its mode of action is
comparable to other taxanes (docetaxel, paclitaxel). DJ-927
binds to tubulin and stabilizes microtubules by inhibiting
their disassembly.2 The drug is manufactured as gelatin
capsules and the intestinal uptake seems to be independent of
P-gp pump.
After oral intake by humans, DJ-927 is protein bound
for 92 to 96% of which 38 to 51% is bound to serum
albumin.3 The drug has its peak concentration after 2 hours
and a slow bi-phasic elimination. It is metabolized in the liver
by the cytochrome phosphate 3A (CYP3A) subfamily of the
cytochrome P450 in the liver.3 The less cytotoxic metabolites
are primarily excreted in the bile and faeces and to a lesser
extent in the urine.3,4 The calculated half-life is 180 hours
with a reproducible and linear PK.
Phase I studies in man have shown dose limiting
toxicity (DLT) at a concentration of 35 mg/m2 and 40 mg/m2
given every 3 weeks. But in pretreated patients, a dose of 35
mg/m2 or less was considered the maximum-tolerated dose.
The dose limiting toxicology profile was primarily hemato-
logical and gastro-intestinal. Therefore, the recommended
dose for further phase II studies was 27 mg/m2 or 35 mg/m2.
The phase II dose was to be confirmed in the first 12 subjects
with NSCLC treated in this study. Based on the noncross
resistance with pretreatment drugs and acceptable toxicity
profile in Phase I, we decided to examine the efficacy of
DJ-927 in an open label phase I/II multicenter setting in
patients with previously treated non-small cell lung cancer.2
PATIENTS AND METHODS
Eligibility Criteria
Patients with histologic or cytologic confirmed locally
advanced or metastatic non-small cell lung cancer were
eligible. Patients must have been treated with one prior
treatment containing a platinum derivative, had documented
progression of the tumor, and measurable disease according
to the response evaluation criteria in solid tumors (RECIST).
They had to have adequate hematologic, renal, and hepatic
function (absolute neutrophil count 1.5 109/liter, platelets
100 109/liter, bilirubin 1.5 upper limit of normal,
Aspartate Serum Amino Transferase and/or Alanine Serum
Amino Transferase2.5 upper limit of normal, unless liver
metastases were present, when values 5 upper of limit
normal, and serum creatinine 1.5 upper limit of normal
were allowed). Eastern Cooperative Oncology Group perfor-
mance score (ECOG) of 0 to 2 was requested. The exclusion
criteria were prior taxane therapy; continuing toxicity related
to the previous antitumor therapy; history of known or sus-
pected brain metastases; prior wide field radiation therapy to
25% of the bone marrow within the last 4 weeks; history of
other malignancies except for resected nonmelanoma skin
cancer or resected carcinoma in situ of the cervix, unless in
complete remission for at least 2 years; the use of medication
that interact with the CYP3A pathway (e.g., cordarone, carba-
mazepine); concurrent infectious diseases or uncontrolled un-
derlying medical disorders; a history of severe hypersensiti-
vity reaction; neurotoxicity or diarrhea grade 2. All toxicities
were graded according to the NCI CTC scoring system
version 3.0.
The study protocol was approved by the medical ethical
committees of all institutes and all patients gave written
informed consent.
Treatment Plan
The first six patients received DJ-927 (Daiichi Sankyo
Co., Ltd.) at a dose of 27 mg/m2 on day one of subsequent 3
weekly periods. When less than two DLTs were observed
during the first course, the next six patients were to receive 35
mg/m2 at during the first course. When less than two DLTs
are observed at 35 mg/m2, the study was to continue at that
dose level. Otherwise, the dosage for all subsequent patients
was to be de-escalated to 27 mg/m2. DLT’s were defined as
febrile neutropenia, neutropenia grade 4 lasting 5 days;
thrombocytopenia (25 109/liter); grade 3 or 4 vomiting or
neurotoxicity; or a dose delay of 1 week after the first
course. If patients fulfill the dose reduction or dose escalation
criteria, DJ-927 dose could be reduced or escalated one dose
level, respectively.
Since the capsules were only available in a fixed dose
of 10 mg, the calculated body surface area (BSA) was
grouped (BSA 1.57: 40 mg; BSA 1.58–1.85: 50 mg;
1.86–2.03: 50 mg; and BSA 2.04: 60 mg). The capsules
were taken orally with 180 cc of water early in the morning
on an empty stomach in an outpatient setting. No antiallergic
medications (dexamethasone, clemastin, and ranitidine) were
taken. To prevent nausea and vomiting, the use of granisetron
or ondansetron was allowed. Retreatment was allowed when
the following conditions were met: absolute neutrophil count
1.5 109/liter; platelet count 100 109/liter; all associ-
ated nonhematological toxicities (excluding alopecia) recov-
ered to either grade 0, grade 1 or baseline value. When
patients did not recover within 2 weeks after the planned start
of the next course, the study treatment was discontinued. A
dose reduction was planned when patients presented with the
above mentioned toxicities but recovered within 2 weeks.
The prophylactic use of G(M)-CSF was allowed after one
dose reduction.
Pharmacokinetic Sampling and Analysis
Sampling for pharmacokinetic (PK) was performed in
every patient during the first course on day 1, 3, 8, and 22. On
day 1 blood samples of 5 cc each were collected in un-
heparinized tubes before dosing, after 15 and 30 minutes and
2, 6, 8, 48, 168, and 504 hours (presecond dose) after
ingestion of DJ-927. Plasma was separated from whole blood
immediate after collection, centrifuged at 3000 rpm for 15
minutes and kept at 20°C until processing. The plasma
concentration of DJ-927 was measured using LC/MS/MS.
The primary PK end point was evaluation of PK of DJ-927 in
plasma by calculating the area under the plasma concentra-
tion time curve (AUC), clearance, maximal plasma concen-
tration (Cmax), time to Cmax (Tmax), and terminal half-life
(T1/2). The AUC was calculated from t  0 to t  168 hours.
The volume of distribution of the steady state/ bio-availability
(Vdss/F) was also calculated.
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PK parameters were obtained by employing noncom-
partimental methods using Winnonlin.
Statistical Analysis
All subjects who were registered in the study were
considered eligible for the Intention to Treat (ITT) population
(n 36) and were summarized for demographic, and primary
and secondary efficacy variables. Any subject who received
study medication was considered eligible for the safety and
toxicity analysis (n 34). Subjects, who received at least one
course of DJ-927 (21 days) and had measurable disease, were
considered eligible for response evaluation (n  28).
The primary end point (best overall response) was
analyzed for both the ITT and the efficacy populations and
95% exact confidence intervals (CI) were calculated using the
Binomial distribution. Tumor response was evaluated using
RECIST. All secondary endpoints were analyzed for the
efficacy population. Key secondary endpoints (time to pro-
gression TTP, time to treatment failure TTF, and median
survival time MST) were analyzed for the ITT and efficacy
populations and Kaplan-Meier survival plots were con-
structed. All safety variables were summarized for the safety
population.
The sample size was determined based on the follow-
ing: Null H0: response rate 3% versus alternative Ha:
response rate was 15%. For this three-outcome, one-stage-
design and  0.05, a sample size of 28 subjects was to yield
type II error  0.2, and power 80%.
RESULTS
Patients Characteristics
A total of 36 patients were included in seven European
centers between October 2004 and September 2005. The
mean age was 58 years (range, 33–75 years) and 75% were
males. Two patients were not included in the analysis because
of refusal (1) or early progression (1) and had not received
any study medication. The patient characteristics are pre-
sented in Table 1. Most patients were in good clinical con-
dition at entry. Six patients did not complete one course of
DJ-927 (3 subjects died due to disease progression and three
patients died due to drug-unrelated adverse events) and were
therefore excluded from the efficacy population.
All patients had received DJ-927 as second-line che-
motherapy for their NSCLC. Thirty-one first line regimen
were cisplatin- and three carboplatin-based doublets. The
most common combination was with gemcitabine (18 of 36
patients), followed by vinorelbine (10), etoposide (7) and
vinblastine (2). Response to first line treatment was CR or PR
in 23 of 36 patients, stable disease in 7 and progressive
disease in five patients.
Response Analysis and Survival
The antitumor activity of DJ-927 was determined by
assessing the subject’s best overall response using RECIST.
A complete response occurred in one patient and in one
patient a partial response was observed, giving an ORR of
5.6% in the ITT group, (Table 2).
Of the 36 patients, 28 (61%) had follow-up scans for at
least 42 days. In this group one patient had a complete
response; one patient a partial response; seven patients had
progressive disease and 17 patients had stable disease. In two
patients the responses could not be evaluated. Of the 17
patients with stable disease, six patients were free of tumors
for more than 150 days.
In this population, the median TTP was 125 days (CI:
57–196 days) and the median TTF was 78 days (CI: 47–118
days). The estimated median survival time was 160 days (CI:
118–353 days).
Toxicity
Thirty-four patients had received at least one cycle of
DJ-927 and were included into the toxicity analysis. Hema-














Response to first line treatment (CR/PR/SD/PD) 1/22/7/5




Large cell 3 (8%)
Undifferentiated 4 (11%)





*Remaining patients had local recurrences.
CR, complete response; PR, partial response; SD, stable disease; PD, partial disease.
TABLE 2. Best Overall Response
Tumor Response
ITT Population (N  36)
No. (%) 95% CI
Complete response 1 3 0.1–14.5
Partial response 1 3 0.1–14.5
CR  PR 2 6 0.7–18.7
Stable disease 17 47 30.4–64.5
Progressive disease 7 20 8.2–36.0
Not evaluable 10 28 14.2–45.2
Tumor response classified according to RECIST by the investigator.
The best overall response is presented in this table. CI, Exact binomial confidence interval.
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tological toxicity was observed in almost all patients. Thir-
teen patients received a dose escalation which was associated
with an increase in hematological toxicity. The grade 3 to 4
hematological toxicities included neutropenia in 18 patients
(53%), leucopenia in 14 patients (41%) and anemia in six
patients (18%). One patient had a febrile neutropenic episode.
The most frequent nonhematologic toxicities are listed in
Table 3.
Twenty-five of the 34 study patients died during the
study. Twelve patients died on study of which eight due to
disease progression and four due to toxicity. Three of them
died because of cardiac related problems. The first patient had
no previous cardiac history but died of heart failure after six
courses of therapy. The second patient had a history of hyper-
tension and coronary vascular disease and died at home with a
suspected cardiac arrest. The third patient was diagnosed 2 years
earlier with heart failure and paroxysmal atrial fibrillation. He
experienced atrial fibrillation for 10 days after the first course
and died of asystoly. No signs of changes in QT time were
observed before or during the treatment. The deaths were not
reported as definitely related to the drug because of previous
cardiac disease. The remaining 13 patients died during the
follow-up phase. Of these patients one developed a fatal pneu-
monia 35 days after he went off study. This event however, was
considered to be possibly related because of a just resolved
neutropenia. In total, there were 191 drug-related AEs, of which
52 of 191 AEs were grade 3 to 5.
The most common reason for going off-study was
progression of the disease in 9 of 34 patients (27%). Six
patients (18%) discontinued due to an AE or unacceptable
toxicity and eight patients (24%) requested to withdraw. One
patient was taken off-study due to noncompliance and one
patient because of clinical deterioration (ECOG performance
status of 4).
Dose Adjustments
All patients received an initial dose level of 27 mg/m2
Subjects received a total of 101 courses during the study
(median number of cycles with range was 2.51–8). At the dose
levels of 18 mg/m2 three courses were given, at a dose level
of 27 mg/m2 71 courses and the dose could be escalated to the
level of 35 mg/m2 for 27 courses. A higher proportion of
treatment courses were associated with grade 3 or 4 neutro-
penia and leucopenia in patients receiving the 35 mg/m2 dose
level. Thirteen patients received one course at the dose level
of 35 mg/kg; 8 received two courses and only three patients
received three or more courses at this level.
Pharmacokinetic Analysis
The PK were evaluated during the first cycle of che-
motherapy after administration of 27 mg/m2 of DJ-927.
Following oral administration, DJ-927 was rapidly absorbed
with a median Tmax value of 2 hours (range, 1–8 hours). The
terminal elimination half-life of DJ-927 was 167  77 hours.
At the 27 mg/m2 dose level, PK analysis showed a Cmax of
42.72  34.3 ng/mL; AUC0–168 of 1752  1355 ng/mL hr;
Vdss/F of 2710 1751 L/m2 and a clearance/F of 12.6 7.3
L/h/m2. The exposure of DJ-927 in subjects with CR and PR
were slightly higher than those who did not respond to
therapy.
DISCUSSION
The standard 2nd line treatment in NSCLC is mono-
therapy with docetaxel.5 Recently, single agent pemetrexed
proved to be as effective and less toxic.6 These regimen
showed a response rate of 5.5 to 8.8% and 9.1% respectively.
Despite these modest response rates, a survival benefit was
obtained and quality of life was generally not compromised.
To improve the benefit of 2nd line therapy for the patient,
changes in the therapeutic index are required. This can be
achieved by a reduction in toxicity, a higher response rate or
by improving the ease of administration. This explains the
growing interest in oral formulations for the treatment of
(lung) cancer. For paclitaxel, the possibility to avoid the
coadministration of Cremophor and its concomitant risk of
anaphylactic reactions is very important. The use of other oral
formulations of paclitaxel have been reported7,8 with accept-
able toxicity and signs of activity. However, the requirement
of cyclosporin to improve the uptake of the oral paclitaxel
and the timing were considered a disadvantage. DJ-927
however bypasses the P450 pump mechanism in the intestinal
mucosal cells due to its special chemical structure, leading to
a better controlled PK profile.
The recommended dose of DJ-927 in this group of
patients with NSCLC was confirmed at 27 mg/m2 with
primarily hematological toxicity, gastro-intestinal toxicity,
and fatigue. The oral formulation resulted in an acceptable
pharmacological profile and initially the ease of administra-
tion was well conceived. The types and incidence rates of
adverse events observed in this study were comparable to
known safety profiles of docetaxel. The most frequent DJ-
927-associated grade 3 or higher toxicities were hematologic
events, with neutropenia as the most common. These hema-
tologic events appeared to be dose-related. Caution must also
be taken with regard to the relative high number of cardiac
deaths in this study whereas none of the investigators con-
sidered the events likely to be related to the investigational
TABLE 3. Nonhematological Toxicity Reported in 5 or
more Patients (Any Grade)
Adverse Events









Nausea 13 (38%) 2 21
Diarrhea 8 (24%) 0 10
Constipation 6 (18%) 0 6
Vomiting 5 (15%) 1 7
Fatigue 15 (44%) 3 20
Weight loss 9 (27%) 1 9
Dyspnea 5 (15%) 2 (grade 4) 8
Anorexia 7 (21%) 3 15




7 (20%) 3 8
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agent. We therefore advice that for future studies close
follow-up with regular ECGs are performed.
In our study population only two patients showed a
radiologic response to DJ-927 (ORR  5,6% in the ITT). In
this phase II study, the response rate of DJ-927 appeared
lower than those reported in other second line studies (Table
4). Many studies with oral agents in the second line setting
have been performed. Of these, some addressed the use of
taxanes. To position this drug in the second line, we have
compared our results with another oral taxane study, oral
vinorelbine, TKIs, and the accepted standard: iv. docetaxel.
Kruijtzer et al. tested the efficacy of an oral taxane and
observed a response rate of 23% and a MST that was
somewhat better with 6 months.1 Other toxicity reported in
our study was primarily hematologic and grade 2 of 3
neurotoxicity. The study by Rossi tested a weekly oral dose
of vinorelbine (60 mg/m2) and observed no responses in 20
patients.15 Since this study did not include any PK analysis,
insufficient blood concentrations might explain this variation.
In addition, differences in patient selection and statistical
variation might attribute to the large variation between these
studies. A large body of data is available for the TKIs like
gefitinib and erlotinib.13,14 From these studies, it has become
clear that the TKIs are potent drugs when proper selection of
the patients is performed (such as EGFR status, EGFR FISH
and mutation, sex, nonsmoking, race etc). For the taxanes, no
such markers have yet been identified.
In comparison to the two phase, 3 randomized studies
with iv. docetaxel, the MST in our study was shorter than
expected. At the dosing schedule used in this trial, we
observed modest anticancer activity with DJ-927 mono-
therapy when given as second line therapy to non-small cell
lung cancer patients, whereas toxicity was more pronounced.
However, the dosing regimen may deserve further explora-
tion. Based on available clinical and PK data, one may prefer
a weekly-three-times schedule, given the relatively long T1⁄2
of the compound. “Metronomic dosing” (i.e., protracted daily
administration of low doses) has been proposed for this class
of compounds, potentially yielding an antiangiogenic effect.
More schedules could be examined to determine a more
favorable therapeutic index.
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